Page 5 - Afmd News Today

StockNews.com downgraded shares of Affimed (NASDAQ:AFMD – Get Rating) from a hold rating to a sell rating in a research report released on Friday morning. A number of other analysts have also issued reports on the company. Truist Financial reduced their target price on Affimed from $12.00 to $8.00 in a report on Monday, December […]

Wells Fargo & Company reissued their overweight rating on shares of Affimed (NASDAQ:AFMD – Get Rating) in a research note published on Monday morning, Benzinga reports. Wells Fargo & Company currently has a $7.00 price objective on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on the stock. […]

StockNews.com lowered shares of Affimed (NASDAQ:AFMD – Get Rating) from a hold rating to a sell rating in a research note released on Friday morning. Several other research firms have also recently weighed in on AFMD. Stifel Nicolaus lowered their price target on Affimed from $2.00 to $1.00 and set a hold rating on the […]

HC Wainwright reissued their buy rating on shares of Affimed (NASDAQ:AFMD – Get Rating) in a report published on Friday morning, Benzinga reports. The brokerage currently has a $6.00 target price on the biopharmaceutical company’s stock. AFMD has been the topic of several other research reports. SVB Leerink decreased their price objective on Affimed from […]

Affimed (NASDAQ:AFMD – Get Rating) had its price objective cut by equities researchers at Stifel Nicolaus from $2.00 to $1.00 in a research report issued to clients and investors on Friday, The Fly reports. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price would suggest a potential upside […]

Affimed (NASDAQ:AFMD – Get Rating)’s share price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $3.04 and traded as high as $3.23. Affimed shares last traded at $3.11, with a volume of 994,125 shares trading hands. Several equities research analysts have recently […]

Shares of Affimed (NASDAQ:AFMD – Get Rating) have received an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price target among […]

Affimed (NASDAQ:AFMD – Get Rating) and AbCellera Biologics (NASDAQ:ABCL – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation. Volatility & Risk Affimed has a beta of 2.51, indicating that […]

Affimed (NASDAQ:AFMD – Get Rating) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 6,200,000 shares, a decline of 18.2% from the April 30th total of 7,580,000 shares. Based on an average daily volume of 1,880,000 shares, the days-to-cover ratio […]

Affimed (NASDAQ:AFMD – Get Rating) will be releasing its earnings data before the market opens on Wednesday, June 1st. Analysts expect Affimed to post earnings of ($0.18) per share for the quarter. Affimed (NASDAQ:AFMD – Get Rating) last announced its quarterly earnings results on Thursday, March 31st. The biopharmaceutical company reported ($0.22) earnings per share […]